Pediatric Genetic Hearing Loss - Clinical Gene Therapy
| Monday, May 5, 2025 |
| 4:00 PM - 5:00 PM |
| C1.2.2 - FOYER |
Details
PANEL
Speaker
Aaron Tward
Eli Lilly/UCSF
Clinical Results Of The Akouos Phase 1/2 Trial Of AAVAnc80-hOTOF
Marimar Medina
Ramon y Cajal Hospital
Results from the CHORD Phase 1/2 Trial: A Open-Label Study Investigating the Safety and Efficacy of DB-OTO Gene Therapy in Children with Profound Deafness Due to Otoferlin Variants
Moderator
Anke Tropitzsch
University Tuebingen
